Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Estrogen-related receptor alpha" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Estrogen-related receptor alpha (ERRα), also known as NR3B1 (nuclear receptor subfamily 3, group B, member 1), is a nuclear receptor that in humans is encoded by the ESRRA (Estrogen Related Receptor Alpha) gene. ERRα was originally cloned by DNA sequence homology to the estrogen receptor alpha (ERα, NR3A1), but subsequent ligand binding and reporter-gene transfection experiments demonstrated that estrogens did not regulate ERRα. Currently, ERRα is considered an orphan nuclear receptor.
SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Estrogen receptor-related receptor alpha (ERRalpha) and cartilage formation
InactiveUS20070054859A1Promote cartilage formationInhibit cartilage formationCompound screeningApoptosis detectionDiseaseMammal
Estrogen related receptor α (ERRα) is involved in control of cartilage formation in mammals. Increasing ERRα activity causes stimulation of cartilage formation, providing a means of therapeutic intervention in diseases such as arthritis which involve cartilage destruction. Compounds may be screened for their potential as therapeutics by screening their effect on ERRα cartilage promoting activity.
Owner:AUBIN JANE E +1
Application of estrogen-related receptor alpha as diagnostic marker for cutaneous squamous cell careinoma and related application of application
InactiveCN107058503APrevent proliferationInhibit migrationMicrobiological testing/measurementBiological material analysisActive componentMedicine
The invention discloses an application of an estrogen-related receptor alpha (ERRalpha) as a diagnostic marker for cutaneous squamous cell careinoma and a related application of the application. The invention discloses an application of the ERRalpha and an active component for lowering or blocking molecular expression of the ERRalpha in cutaneous squamous cell careinoma in preparation of related kits and drugs for diagnosing and treating cutaneous squamous cell careinoma. Novel diagnosis and treatment means are provided for treatment of cutaneous squamous cell careinoma.
Owner:复旦大学附属华山医院北院
Use of estrogen-related receptor alpha as diagnostic marker for glioma and related application
InactiveCN107604060APrevent proliferationInhibit migrationMicrobiological testing/measurementBiological testingEstrogen-related receptor alphaGlioma
The present invention discloses use of estrogen-related receptor alpha (ERR alpha) as a diagnostic marker for glioma and related application, also discloses application of the ERR alpha and an activecomponent for down-regulating or blocking of expression of ERR alpha molecule in the glioma in preparation of a related kit and drug for diagnosis and treatment of the glioma, and provides a new method for diagnosis and treatment of the glioma.
Owner:复旦大学附属华山医院北院
Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators
Owner:JANSSEN PHARMA NV
Application of carnosic acid in preparing ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and medicine for treating osteoporosis
The invention discloses application of carnosic acid in preparing an ERRalpha (Estrogen-Related Receptor alpha) expression inhibitor and a medicine for treating osteoporosis. Through in-vitro experiments, the inventor finds that carnosic acid is an effective ERRalpha expression inhibitor and is capable of inhibiting expression of related osteoporosis markers in osteoporosis cell models; in-vivo experiments show that due to adoption of the carnosic acid, physiological phenomena (such as tibia BV / TV reduction, tibia Tb.Th reduction, tibia Tb.N reduction, tibia Tb.SP increase and tibia SM1 increase) caused by mouse ovary excision are reversed to a certain extent, then bone defects (such as bone substance reduction and / or microstructure degradation of bone) caused by estrogen deficiency symptoms can be treated, and the carnosic acid has the prospect of being developed into medicines for treating osteoporosis caused by menopause.
Owner:CHINA PHARM UNIV
Compound promoting activity of estrogen related receptor alpha (ERR alpha), and its use
InactiveCN102924561ASlow down the phenomenon of osteoporosisOrganic active ingredientsSkeletal disorderDrugEstrogen-related receptor alpha
The invention relates to a compound and its use, and especially relates to a compound promoting the activity of ERR alpha, and its use in the preparation of medicines treating the osteoporosis. The compound can improve the menopausal osteoporosis phenomena.
Owner:I-SHOU UNIVERSITY
A kind of 4-bromophenylurea compound that regulates the activity of estrogen-related receptors and its medical application
The invention discloses a novel 4-bromophenylurea compound with formula I for regulating estrogen-related receptor activity, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH
A novel n-p-tolyl-benzamide compound that regulates the activity of estrogen-related receptors and its medical application
The invention discloses a novel N-p-tolyl-benzamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH
Novel N-phenyl-benzamide-based estrogen-related receptor activity regulating compound and medical uses thereof
The present invention discloses a novel N-phenyl-benzamide-based estrogen-related receptor activity regulating compound having a structure represented by a formula I, a pharmaceutically acceptable salt and applications thereof, wherein the compound and the pharmaceutically acceptable salt thereof can be used for preparation of drugs for regulating the activity of estrogen-related receptors ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRalpha) and preventing and treating breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer, cervical cancer and other malignant tumors. The formula I is defined in the specification.
Owner:QILU UNIV OF TECH
Novel 3-bromophenyl urea estrogen-related receptor activity regulation compound and medical use thereof
The invention discloses a novel 3-bromophenyl urea estrogen-related receptor activity regulation compound, its pharmaceutically acceptable salt and application thereof. The compound and its pharmaceutically acceptable salts can be used for preparation of drugs capable of regulating estrogen related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERR alpha) activity, preventing and treating breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer, cervical cancer and other malignant tumors. (formula I).
Owner:QILU UNIV OF TECH
Novel N-isopropyl-benzamide compound for adjusting activity of estrogen-related receptor and medical application of novel N-isopropyl-benzamide compound
InactiveCN106551922AAmide active ingredientsAntineoplastic agentsMedicineEstrogen-related receptor alpha
The invention discloses a novel N-isopropyl-benzamide compound (with a formula I) for adjusting activity of an estrogen-related receptor, medical acceptable salt of the novel N-isopropyl-benzamide compound and an application of the novel N-isopropyl-benzamide compound. The compound and the medical acceptable salt of the compound can be used for preparing drugs capable of adjusting the activity of the estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERR alpha) and preventing and curing the breast cancer, the prostatic cancer, the stomach cancer, the colon cancer, the ovarian cancer, the cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH
A novel 2-benzyloxy-benzoic acid ester compound that regulates the activity of estrogen-related receptors and its medical application
Owner:QILU UNIV OF TECH
Novel bipropoxyphenyl-methylsulfonylamide compound for adjusting activity of estrogen-related receptor and medical purpose thereof
The invention discloses a novel bipropoxyphenyl-methylsulfonylamide compound (as shown in the formula I) for adjusting activity of an estrogen-related receptor and pharmaceutically acceptable salt and application thereof. The compound and the pharmaceutically acceptable salt can be used in preparation of medicines for adjusting activity of the estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRalpha) and preventing and treating malignant tumors such as breast cancer, prostate cancer, stomach cancer, colorectal carcinoma, ovarian cancer, cervical carcinoma, etc.
Owner:QILU UNIV OF TECH
A novel n-phenyl-benzamide compound that regulates the activity of estrogen-related receptors and its medical application
Owner:QILU UNIV OF TECH
A novel 3-methoxyphenyl-benzamide compound for regulating estrogen-related receptor activity and its medical use
InactiveCN106543046BOrganic chemistryAmide active ingredientsActivity regulationEstrogen receptor activity
Owner:QILU UNIV OF TECH
Novel estrogen-related receptor alpha inhibitor and medical application thereof
The invention discloses a novel estrogen-related receptor alpha (ERR alpha) inhibitor, which is a compound of a formula I and pharmaceutically acceptable salt or solvate thereof. A pharmaceutical composition containing the compound can be used for preparing medicines for preventing and treating diseases including mammary cancer, cervical carcinoma, ovarian cancer, prostatic cancer, stomach cancer, colon cancer and the like.
Owner:CHINA PHARM UNIV
Novel 2-benzyloxy-phenyl formic acid ester compound for regulating activity of estrogen-related receptor as well as medical applications thereof
The invention discloses a novel 2-benzyloxy-phenyl formic acid ester compound for regulating activity of estrogen-related receptor with a formula I as well as pharmaceutically acceptable salts and applications thereof. The compound and pharmaceutically acceptable salts are used for preparing activity of ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRalpha), and are used for preparing medicaments for preventing and treating breast cancer, prostatic cancer, stomach cancer, colorectal carcinoma, ovarian cancer, cervical carcinoma and other malignant tumors.
Owner:QILU UNIV OF TECH
A novel dipropoxyphenyl-methanesulfonamide compound for regulating estrogen-related receptor activity and its medical use
InactiveCN106565551BOrganic chemistryAmide active ingredientsProstate cancerReceptor for activated C kinase 1
Owner:QILU UNIV OF TECH
Novel 3-methoxyphenyl-benzamide estrogen-related receptor activity regulation compound and medical use thereof
The invention discloses a novel 3-methoxyphenyl-benzamide estrogen-related receptor activity regulation compound with a structure shown as formula I, its pharmaceutically acceptable salt and application thereof. The compound and its pharmaceutically acceptable salts can be used for preparation of drugs capable of regulating estrogen related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERR alpha) activity, preventing and treating breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer, cervical cancer and other malignant tumors. (formula I).
Owner:QILU UNIV OF TECH
Novel estrogen-related receptor alpha agonists and application thereof
ActiveCN110563681AStrong agonistic activityNovel structureOrganic chemistryMetabolism disorderBenzoic acidScreening method
The invention relates to novel estrogen-related receptor alpha (ERRalpha) agonists. The novel ERRalpha agonists are 7,8-dimethyl-4-(1-piperidyl)-2H-1-benzopyran-2-one, 2,4-dichloro-1-naphthyl-1-nipecotic acid, 2-[(hexyloxy-1(2H)-azoheterocyclic)methyl]-8-methyl-4H-pyridino[1,2-a]pyrimidone, 7-chloro-2-[(4-methyl-1-piperidyl)methyl]-4(3H)-quinazolinone, N-[5-[(2-amino-2-oxoethyl)thio]-2-thiazolyl]-3-methyl-1-phenyl-1H-thiophene[2,3-c]pyrazol-5-carboxamide and 4-[(2,4-dichlorophenyl)methoxy]-3-methoxy-2-amino-1-methyl-2-oxoethyl-benzoic acid. The invention further provides a screening method andan application of the novel ERRalpha agonists.
Owner:EAST CHINA UNIV OF SCI & TECH
Novel N-p-methylphenyl-benzamide estrogen-related receptor activity regulating compound and medical application thereof
InactiveCN106543047AOrganic chemistryAmide active ingredientsMedicineEstrogen-related receptor alpha
The invention discloses a novel N-p-methylphenyl-benzamide estrogen-related receptor activity regulating compound with a formula I, pharmaceutically acceptable salt of the compound and an application of the compound. The compound and the pharmaceutically acceptable salt thereof can be used for preparing a medicine with the functions of regulating ERR-alpha (estrogen-related receptor alpha) or ERR alpha activity and preventing and treating malignant tumors such as breast cancer, prostatic cancer, stomach cancer, colon cancer, ovarian cancer and cervical cancer).
Owner:QILU UNIV OF TECH
Aminothiazolones as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Aminothiazolones as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Novel 3-methoxybenzyl-benzamide compound for adjusting activity of estrogen-related receptor alpha and medical application thereof
InactiveCN106543048AOrganic chemistryAmide active ingredientsCervical cancerReceptor for activated C kinase 1
The invention discloses a novel 3-methoxybenzyl-benzamide compound, as shown in a formula I which is described in the specification, for adjusting the activity of an estrogen-related receptor alpha and a pharmaceutically salt thereof, and medical application thereof. The compound and the pharmaceutically salt thereof can be used for preparing drugs capable of adjusting the activity of the estrogen-related receptor alpha (ERR-alpha) and preventing and treating malignant tumors like breast cancers, prostatic cancers, stomach cancers, colorectal cancers, ovarian cancer and cervical cancers.
Owner:QILU UNIV OF TECH
A 3-bromophenylurea compound for regulating estrogen-related receptor activity and its medical use
The invention discloses a novel 3-bromophenylurea compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salt can be used for the preparation of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH
Novel 4-bromophenylurea-type compound with estrogen-related receptor regulation activity and its medical use
The invention discloses a novel 4-bromophenylurea-type compound with estrogen-related receptor regulation activity and its pharmaceutically acceptable salt and use. The compound is shown in the formula I. The compound and its pharmaceutically acceptable salt are used for preparation of drugs which have estrogen-related receptor alpha (ERR-alpha) regulation activity and are used for preventing and treating cancers such as breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer and cervical cancer.
Owner:QILU UNIV OF TECH
Novel p-methoxybenzyl-benzamide type compound for regulating estrogen-related receptor activity and medical use thereof
InactiveCN106551921AAmide active ingredientsAntineoplastic agentsEstrogen-related receptor alphaOvarian cancer
The invention discloses a novel p-methoxybenzyl- benzamide type compound (as shown in the formula I) for regulating estrogen-related receptor activity and pharmaceutically acceptable salt and application thereof. The compound and its pharmaceutically acceptable salt can be used for preparation of a medicine for regulating activity of estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERR alpha) and preventing and treating malignant tumors such as breast cancer, prostatic cancer, stomach cancer, colorectal carcinoma, ovarian cancer, cervical carcinoma, etc.
Owner:QILU UNIV OF TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com